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The biologic functions of gangliosides GM3 and GD3 in
the attachment of human melanoma cells to extracellular
matrix proteins (type I and IV collagens, fibronectin, and
laminin) were investigated by using the GD3-deficient
mutant clone (SK-MEL-28-N1) and the parent cell line
SK-MEL-28. SK-MEL-28-N1 (N1) (high GM3 expression:
GM3, 97.3%; GD3, 0%) was selected by treating SK-MEL-
28 (high GD3 but low GM3: GM3, 6.5%, GD3, 93.5%)
with an anti-GD3 monoclonal antibody (R24) and rabbit
complement and subsequent subcloning of the surviving
cells. The N1 clone showed significantly higher ability to
adhere to type I and IV collagens and laminin than the
parent clone SK-MEL-28. In the N1 clone, the expression
of a2b1 and a3b1 integrin receptors was increased,
Gangliosides (sialylated glycosphingolipids) are ubiquit-ously expressed on mammalian plasma membranes.They have been considered to be receptors for exo-genous as well as endogenous molecules, regulatorsof cellular differentiation and proliferation, molecules
involved in cellular adhesion (Zheng et al, 1993; Paller et al, 1995),
and modulators of the immune response (Nojiri et al, 1986; Kojima
and Hakomori, 1989; Livingston et al, 1989; Furukawa and Lloyd,
1990). Gangliosides have also been considered to be related to tumor
progression and prognosis (Ravindranath et al, 1991; Nakano et al,
1992, 1997).
Gangliosides GM3 and GD3 are major gangliosides of melanoma
(Tsuchida et al, 1987; Furukawa and Lloyd, 1990). Several functions
of GM3 and GD3 of melanoma have been reported. Both GM3 and
GD3 have been considered to be melanoma-associated antigens and
targets for antibody-based and vaccine-based therapies for melanoma
(Houghton et al, 1985; Helling et al, 1994; Ota et al, 1995). GM3 of
mouse melanoma suppressed immunoresponses by inhibiting the
activity of cytotoxic T lymphocytes (CTL) in the effector phase and
by induction of specific suppressor T lymphocytes that block CTL
generation in the induction phase (Takahashi et al, 1988). In both
mouse and human melanomas, cell lines with high expression of GM3
had a higher metastatic ability than those with low GM3 expression
(Nozue et al, 1988; Zebda et al, 1995). Treatment with monoclonal
antibodies directed specifically to the carbohydrate moiety of GD3
inhibited melanoma cell attachment to various adhesive proteins, and
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whereas in SK-MEL-28, their expression was very low or
undetectable. The treatment with monoclonal antibodies
directed specifically to GD3 expressed on SK-MEL-28
inhibited the cell attachment to type IV collagen (33%
inhibition of control), fibronectin (59%), and laminin
(71%). These findings suggest that gangliosides GM3 (by
influencing integrin receptor levels) and GD3 (by inter-
acting directly with matrix proteins) might play some
functional roles in attachment to extracellular matrix
proteins and thereby enhance the metastatic potency of
melanoma cells. Key words: cell adhesion/collagen/fibronec-
tin/laminin. Journal of Investigative Dermatology Symposium
Proceedings 4:173–176, 1999
these results suggested that GD3 might play a role in cell attachment
of melanoma (Cheresh et al, 1986). Previously, we reported the isolation
of GD3-deficient cell lines by treating parental SK-MEL-28 cells with
an anti-GD3 antibody and rabbit complement. These mutant cell lines
showed poor growth in vitro and in vivo in nu/nu mice and these
findings suggested that GD3 had some specific roles in cell proliferation
(Nakano et al, 1996).
Using human melanoma GD3-deficient mutant cell line, SK-MEL-
28-N1 (characterized by high GM3 content), and the parental cell
line, SK-MEL-28 (which has high GD3 content but low GM3), we
investigated the biologic roles of GM3 and GD3 in attachment of cells
to extracellular matrix proteins.
MATERIALS AND METHODS
Cell lines and culture conditions Human melanoma cell line, SK-MEL-
28, and GD3-deficient cell line, SK-MEL-28-N1 (N1), have been described
previously (Nakano et al, 1996). In brief, N1 was selected by treating SK-MEL-
28 with an anti-GD3 monoclonal antibody (R24) and rabbit complement and
subsequent subcloning of surviving cells. The cell lines were cultured in Eagle’s
minimal essential medium supplemented with fetal bovine serum (FBS, 10%),
L-glutamine (2 mM), nonessential amino acid (1%), and penicillin–streptomycin
(100 IU and 100 µg per ml).
Monoclonal antibodies (MoAb) R24 (anti-GD3; IgG3) and DH2 (anti-
GM3; IgG3) have been described previously (Pukel et al, 1982; Nores et al,
1987). GMR19 (anti-GD3; IgM) (Ozawa et al, 1992) was kindly provided by
Dr T. Tai of the Tokyo Metropolitan Institute of Medical Science. Monoclonal
mouse anti-human integrin antibodies (anti-α2β1, IgG1; anti-α3β1, IgG1; anti-
α4β1, IgG3; anti-α5β1, IgG3) were purchased from DAKO (Carpinteria, CA).
Glycolipid isolation and thin-layer chromatography (TLC) Isolation of
gangliosides from melanoma cells and TLC of the isolated gangliosides were
carried out as described previously (Nakano et al, 1996). Ganglioside composition
was estimated by photodensitometric scanning with a Shimadzu TLC scanner
(SC930).
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Figure 1. TLC of gangliosides extracted from two melanoma clones.
Lane 1, SK-MEL-28; lane 2, N1; S, standard gangliosides. The samples
were developed on a high-performance TLC plate in a solvent system
of chloroform:methanol:0.2% aqueous CaCl2 (55:45:10). Gangliosides were
visualized by spraying with resorcinol-HCl reagent.
Table I. Ganglioside composition (%)
Cell line GM3 GD3 Others
SK-MEL-28 6.5 93.5 0
N1a 97.3 0 2.7
aGD3-deficient mutant cell line of SK-MEL-28.
Table II. Reactivity of anti-ganglioside MoAb with melanoma
cell lines assayed by indirect immunofluorescent staining
Anti-GD3
Cell line R24 GMR19 Anti-GM3, DH2
SK-MEL-28 ,3.125a(31)c 16b(1) 0
N1 0 0 2b(6)
aLast concentration showing positive cells (µg per ml).
bLast dilution showing positive cells.
cEstimate of strength of reaction: 31, very strong; 21, strong; 1, weak; 6, very weak.
Indirect immunofluorescent staining Cells were allowed to attach onto
60 well plates for 24 h. The cells were washed twice with phosphate-buffered
saline (PBS). Antibodies were serially diluted 2-fold in microtiter plates and
were added to each well (10 µl per well). The plates were incubated for 45 min
at room temperature. The plates were washed twice and the cells were
incubated with 10 µl of fluorescein isothiocyanate-conjugated rabbit anti-mouse
immunoglobulins (1:100; DAKO A/S, Glostrup, Denmark) for 45 min at room
temperature. After two washes with PBS, the cells were examined with a
fluorescent microscope.
Adhesion assay Rat tail collagen type I, mouse collagen type IV, human
fibronectin, and mouse laminin-coated 24 well plates (BIOCOAT Cellware)
were purchased from Collaborative Biomedical Products–Becton Dickinson
(Bedford, MA). Before addition of cells, wells were precoated with PBS
containing 1% bovine serum albumin for 1 h to block nonspecific binding sites.
Cells (5 3 104 per well) were added to matrix-coated 24 well plates and
incubated for 60, 120, 180, and 240 min at 37°C in a humidified incubator
containing 5% CO2. At each interval, the plates were inverted to facilitate the
removal of unbound cells, and all wells were washed twice with PBS. The
remaining attached cells were harvested by trypsinization and numbers were
counted with a microscope and a hemocytometer.
Antibody inhibition assay The cells were detached with 1 mM EDTA in
PBS. The cells were washed with growth medium containing 1% FBS and
4 3 106 cells were incubated with saturating concentrations of antibodies
(500 µl) as follows: R24 (20 µg per ml), GMR19, and DH2 (culture supernatant).
After incubation for 1 h at 4°C, the cells were washed twice and resuspended
with growth medium containing 1% FBS. Cells (1 3 105 per well) were plated
onto bovine serum albumin-blocked matrix-coated 24 well plates and incubated
for 60 (for type I, IV collagens and fibronectin) or 120 min (for laminin) at
37°C in a humidified incubator containing 5% CO2. At each interval, the
plates were inverted to facilitate the removal of unbound cells, and all wells
Figure 2. Cell adhesion to various substrates. Cell adhesion was estimated
as described in Materials and Methods. Error bars: mean6SD. **p,0.01; *p,0.02;
†p,0.05 vs SK-MEL-28. u, N1; O, SK-MEL-28.
were washed twice with PBS. The remaining attached cells were harvested by
trypsinization and numbers were counted.
RESULTS AND DISCUSSION
Ganglioside composition of melanoma cell lines As shown in
Fig 1 and Table I, the ganglioside composition of SK-MEL-28 was
GM3, 6.5%, GD3, 93.5%, and GD2, 0%, and that of N1 was GM3,
97.3%, GM2, 2.7%, GD3, 0%, and GD2, 0%.
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Table III. Reactivity of anti-human integrin receptor MoAb
with melanoma cell lines assayed by indirect
immunofluorescent staining
Anti-human integrin receptors
Cell line α2β1 α3β1 α4β1 α5β1
SK-MEL-28 0 4a 0 0
N1 128a**(31)b 256,a**(31) 2a(6) 0
aLast dilution showing positive cells.
bEstimate of strength of reaction: see the footnote of Table II. **p,0.01 vs SK-MEL-28.
Reactivity of antiganglioside monoclonal antibodies with
melanoma cell lines As described previously, SK-MEL-28 reacted
strongly with anti-GD3 MoAb but N1 cells were nonreactive, con-
firming the absence of GD3 in this cell line (Nakano et al, 1996). Anti-
GM3 MoAb was reactive, although very weakly, with the N1 clone
and not with SK-MEL-28 (Table II).
Cell attachment to various extracellular matrix proteins The
attachment to various extracellular matrix proteins of a mutant clone
of SK-MEL-28 cells (N1) and its parent cell line, which differ in
ganglioside composition, was first studied. As shown in Fig 2, after
4 h incubation in matrix-coated wells, adhesion of N1 clone cells to
type I and IV collagens and laminin was significantly greater than that
of SK-MEL-28. In contrast, cell attachment to fibronectin did not
differ significantly among the clones. Nozue et al (1988) reported that
GM3 of mouse melanoma cell lines enhanced cell attachment to both
type IV collagen and laminin. On the other hand, incorporation of
GM3 into the keratinocyte membrane did not affect the cell adhesion
to matrix proteins (Paller et al, 1995). These results suggest that GM3
of human melanoma cells also has a role, either directly or indirectly,
in the cell attachment of these matrices.
Expression of integrin receptors of melanoma clones Expression
of integrin receptors (α2β1, α3β1, α4β1, α5β1) on each clone was
examined with an indirect immunofluorescent staining method. In the
N1 clone cells, expression of α2β1 and α3β1 integrin receptors was
increased compared with SK-MEL-28 cells, in which their expression
was very low or undetectable (Table III). α2β1 and α3β1 are integrin
receptors for collagens and laminin. It seemed that the increased ability
of N1 clone cells to adhere to collagens and laminin was due to the
increase in the expression of integrin receptors. Interactions between
specific gangliosides and integrin molecules are known. For example,
GM3 of a mouse mammary carcinoma mutant cell line enhances the
function of the α5β1 integrin receptor for fibronectin-mediated
adhesion (Zheng et al, 1993), and GD2 of neuroblastoma tumor cells
enhances α2β1 integrin-dependent platelet adhesion (Valentino and
Ladisch, 1996). The results of this study indicate that GM3 might play
an indirect role by enhancing the expression of integrin receptors.
Inhibition of cell attachment with antiganglioside anti-
bodies Treatment of SK-MEL-28 cells with monoclonal antibodies
directed specifically to GD3 inhibited the cell adhesion of these cells
to type IV collagen (33% of control: no antibody), fibronectin (up to
59%), and laminin (up to 71%) (Fig 3). An anti-GM3 antibody (DH2)
did not inhibit the cell attachment of N1 (data not shown). It seemed
that the reactivity of DH2 to N1 was too weak to inhibit the cell
attachment to matrix proteins. These results are consistent with the
report of Cheresh et al (1986) that MoAb to GD3 and GD2 inhibited
melanoma cell attachment to various adhesive proteins.
The findings of this study suggest that gangliosides GM3 and GD3
might play functional roles in attachment of melanoma cells to
extracellular matrix proteins. GM3 may be involved indirectly by
influencing the expression of integrin receptors on the cells. As the
ability of cells to adhere to extracellular matrix proteins is important
in metastasis, it follows that GM3 and GD3 ganglioside levels could be
involved in mediating the metastasis of melanoma cells.
Figure 3. The effects of monoclonal anti-ganglioside antibodies (R24,
anti-GD3; GMR19, anti-GD3; DH2, anti-GM3) on binding of SK-MEL-
28 cell lines to various substrates. Cell adhesion was estimated as described
in Materials and Methods. Error bars: mean6SD. **p,0.01; *p,0.02 vs control
(no antibody).
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